Find information on thousands of medical conditions and prescription drugs.

Neuroleptic malignant syndrome

Neuroleptic malignant syndrome (NMS) is a life-threatening, neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs. It is considered to be a very serious neurological disorder. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
Narcolepsy
Necrophobia
Necrotizing fasciitis
Neisseria meningitidis
Nemaline myopathy
Neonatal hemochromatosis
Neophobia
Nephophobia
Nephrogenic diabetes...
Nephrotic syndrome
Neuraminidase deficiency
Neurasthenia
Neuroacanthocytosis
Neuroblastoma
Neurofibrillary tangles
Neurofibroma
Neurofibromatosis
Neurofibromatosis type 2
Neuroleptic malignant...
Niemann-Pick Disease
Nijmegen Breakage Syndrome
Nocardiosis
Noma
Non-Hodgkin lymphoma
Noonan syndrome
Norrie disease
Nosophobia
Nyctophobia
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Causes

NMS is caused almost exclusively by antipsychotics, which includes all types of neuroleptic medicines along with newer antipsychotic drugs. The higher the dosage, the more common the occurrence. Rapid and large increases in dosage can also be attributed to the development of NMS. Other drugs, environmental or psychological factors, hereditary conditions, and specific demographics may be at greater risk, but to date no conclusive evidence has been found to support this. The disorder typically develops within two weeks of the initial treatment with the drug, but may develop at any time that the drug is being taken. NMS may also occur in people taking a class of drugs known as dopaminergics.

Symptoms

The first symptom to develop is usually muscular rigidity, followed by high fever and changes in cognitive functions. Other symptoms can vary, but may be unstable blood pressure, confusion, coma, delirium, muscle tremors, etc. Once symptoms do appear, they rapidly progress and can reach peak intensity in no more than three days. These symptoms can last as little as eight hours or as long as forty days.

Prognosis

As with most illnesses, the prognosis is best when identified early and treated aggressively. In these cases, NMS is usually not fatal, although there is currently no agreement on the exact mortality rate for the disorder. Studies have given the disorder a mortality rate as low as 5% and as high as 76%, although most studies agree that the correct percentage is in the lower spectrum, perhaps between 10% - 20%. Re-introduction to the drug that originally caused NMS to develop may also trigger a recurrence, although in most cases it does not.

Treatment

Although treatment is not always necessary, it will help to cure the disease and prevent fatal developments from occurring. The first step in treatment is generally to remove the patient from any neuroleptic or antipsychotic drugs being taken and to treat fever agressively. Many cases require intensive care, or some kind of supportive care at the minimum. Depending on the severity of the case, patients may require other treatments to contend with specific effects of the disorder. These include circulator and ventilatory support, the drugs dantrolene sodium, bromocriptine, apomorphine and electroconvulsive therapy (ECT) if medication fails.

Read more at Wikipedia.org


[List your site here Free!]


Risperidone and neuroleptic malignant syndrome
From Nursing, 3/1/97 by Shuster, Joel

A 53-YEAR-OLD WOMAN WITH CHRONIC psychosis began treatment with the antipsychotic drug risperidone (Risperdal), 1 mg b.i.d., along with 1 mg b.i.d. of the antiparkinsonian agent benztropine (Cogentin), a drug prescribed to avert possible adverse reactions to risperidone. Over the next 3 days, her practitioner increased the risperidone dosage to 3 mg b.i.d. On day four, the patient complained of muscle pain and stiffness. She also had diaphoresis, muscle rigidity, and a masklike expression. Her pulse was 110; respirations, 24; and temperature, 99.5 F (37.5o C). Her creatine kinase (CK) level was high-907 international units/liter (normal is 135 international units/liter) and her white blood cell (WBC) count was normal. Her practitioner discontinued the risperidone, and the patient improved within a few days.

What went wrong?

The patient suffered from an adverse drug reaction (ADR) to risperidone. The ADR-neuroleptic malignant syndrome (NMS)-is a rare, potentially fatal disorder that affects 0.5% to 1% of patients receiving antipsychotics (also referred to as neuroleptics). Usually, NMS is associated with high-potency antipsychotics such as haloperidol (Haldol), but other antipsychotics also can trigger it.

Patients may develop tachycardia, diaphoresis, a fever as high as 106deg F (41deg C), blood pressure changes, dyspnea, and incontinence; CK levels and WBC counts are usually elevated. Extrapyramidal signs may include pseudoparkinsonism, generalized muscle rigidity, or catatonic-like behavior. Bromocriptine and dantrolene may be used to treat the symptoms of NMS.

What precautions can you take?

Teach your patient to recognize the symptoms of NMS, such as tachycardia and muscle rigidity. If she experiences NMS symptoms, tell her to stop taking risperidone and notify her practitioner. If NMS isn't recognized early, it can be fatal.

Copyright Springhouse Corporation Mar 1997
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Neuroleptic malignant syndrome
Home Contact Resources Exchange Links ebay